OverviewSuggest Edit
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
| Type | Public | |
| Founded | 2001 | |
| HQ | Needham, MA, US | Map |
| Website | chiasmapharma.com | |
| Employee Ratings | More |
Recent NewsAll News
- Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
- Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency
- Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
- Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
Key People/Management at Chiasma
Roni Mamluk
CEO
Dana Gelbaum
VP of BD and Supply Chain
Shoshie Katz
VP of Quality Assurance & Regulatory Affairs
Asi Haviv
VP of Clinical Development
Lillian Kuan
Alumni Advisory Committee Board Member
Chiasma Office Locations
Chiasma has offices in Needham, Waltham and Ness Ziona
Needham, MA, US (HQ)
140 Kendrick St Building C
Waltham, MA, US
460 Totten Pond Rd #530
Ness Ziona, IL
5 Golda Me'ir St
Chiasma Financials and Metrics
Chiasma Revenue
Chiasma's revenue was reported to be $1.11 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 1.9m |
Gross profit (Q1, 2021) | 1.9m |
Gross profit margin (Q1, 2021), % | 96.5% |
Net income (Q1, 2021) | (30.5m) |
EBIT (Q1, 2021) | (18.0m) |
Market capitalization (9-Aug-2021) | 217.5m |
Closing stock price (9-Aug-2021) | 3.8 |
Cash (31-Mar-2021) | 24.6m |
EV | 193.5m |
Chiasma's current market capitalization is $217.5 m.
Annual
Annual
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 63.3m | 140.9m | 39.1m | 30.5m | 28.5m | 19.0m | 18.4m | 12.1m | 15.2m | 13.8m | 11.2m | 10.1m | 20.6m | 19.7m | 42.6m | 52.2m | 72.8m | 24.6m |
Accounts Receivable | 179.0k | 1.0m | ||||||||||||||||
Prepaid Expenses | 466.0k | 1.4m | 3.8m | 2.5m | 2.2m | 1.8m | 1.4m | 2.2m | 1.7m | 1.2m | 1.7m | 1.4m | 1.1m | 3.0m | 4.9m | 3.7m | 5.4m | 6.6m |
Inventories | 8.9m | 14.4m |
Annual
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (12.0m) | (21.4m) | (17.2m) | (43.8m) | (53.2m) | (7.0m) | (13.9m) | (20.7m) | (7.0m) | (15.7m) | (23.2m) | (8.7m) | (16.6m) | (24.3m) | (15.4m) | (36.5m) | (55.0m) | (30.5m) |
Depreciation and Amortization | 98.6k | 146.2k | 59.0k | 153.0k | 373.0k | 40.0k | 79.0k | 119.0k | 23.0k | 46.0k | 69.0k | 16.0k | 29.0k | 42.0k | 26.0k | 73.0k | 122.0k | 51.0k |
Inventories | (8.9m) | (3.4m) | ||||||||||||||||
Accounts Payable | 358.5k | 366.0k | (457.0k) | (670.0k) | (613.0k) | 1.7m | 3.1m | 3.2m | (751.0k) | (1.2m) | (1.9m) | 2.9m | 5.8m | 7.7m | 596.0k |
| USD | Q2, 2015 |
|---|---|
Financial Leverage | -0.8 x |
Chiasma Cybersecurity Score
Chiasma Online and Social Media Presence
198 Twitter followers
Chiasma has 198 Twitter Followers. The number of followers has decreased 0.1% month over month and increased 1.7% quarter over quarter
Chiasma's Trends
Chiasma News and Updates
August 05, 2021
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
Amryt Successfully Completes Acquisition of Chiasma, Inc.
June 28, 2021
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency
Submission supported by previously announced data from Phase 3 MPOWERED™ study Submission supported by previously announced data from Phase 3 MPOWERED™ study
June 28, 2021
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
June 15, 2021
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
May 20, 2021
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting --
May 08, 2021
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA
NEW YORK, May 7, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
Chiasma Blogs
June 25, 2021
Labadzhyan A, Nachtigall LB, Fleseriu M, et al. Oral Octreotide Capsules for the Treatment of Acromegaly: Comparison of 2 Phase 3 Trial Results. Pituitary. 2021. https://doi.org/10.1007/s11102-021-01163-2
The post Labadzhyan A, Nachtigall LB, Fleseriu M, et al. Oral Octreotide Capsules for the Treatment of Acromegaly: Comparison of 2 Phase 3 Trial Results. Pituitary. 2021. https://doi.org/10.1007/s11102-021-01163-2 appeared first on Chiasma.
May 27, 2021
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- NEEDHAM, Mass. , May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA),...
The post Chiasma Presents Positive Patient-R…
May 22, 2021
Gordon MB, Fleseriu M, Dreval AV, et al. Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands In The MPOWERED Trail. Endocrine Abs. 2021; 73: PEP13.6. https://doi.org/10.1530/endoabs.73.PEP13.6
The post Gordon MB, Fleseriu M, Dreval AV, et al. Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands In The MPOWERED Trail. Endocrine Abs. 2021; 73: PEP13.6. https://doi.org/10.1530/endoabs.73.PEP13.6 appeared first on Chiasm…
May 22, 2021
Fleseriu M, Dreval AV, Pokramovich Y, et al. A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. Endocrine Abs. 2021; 73: OC13.6. https://doi.org/10.1530/endoabs.73.OC13.6
The post Fleseriu M, Dreval AV, Pokramovich Y, et al. A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. Endocrine Abs. 2021; 73: OC13.6. https://doi.org/10.1530/endoabs.73.OC13.6…
May 22, 2021
Biermasz N, Fleseriu M, Dreval AV, et al. Oral Octreotide Capsules Lowered Incidence And Improved Severity of Acromegaly Symptoms Compared To Injectable Somatostatin Receptor Ligands—Results From The MPOWERED Trial. Endocrine Abs. 2021; 73: PEP8.1. https://doi.org/10.1530/endoabs.73.PEP8.1
The post Biermasz N, Fleseriu M, Dreval AV, et al. Oral Octreotide Capsules Lowered Incidence And Improved Severity of Acromegaly Symptoms Compared To Injectable Somatostatin Receptor Ligands—Results From The MPOWERED Trial. Endocrine Abs. 2021; 73: PEP8.1. https://doi.org/10.1530/endoabs.73.PEP8.1 …
May 22, 2021
Freda P, Fleseriu M, Dreval AV, et al. Safety Results From MPOWERED, A Phase 3 Trial Of Oral Octreotide Capsules In Adults With Acromegaly. Endocrine Abs. 2021; 73: PEP3.2. https://doi.org/10.1530/endoabs.73.PEP3.2
The post Freda P, Fleseriu M, Dreval AV, et al. Safety Results From MPOWERED, A Phase 3 Trial Of Oral Octreotide Capsules In Adults With Acromegaly. Endocrine Abs. 2021; 73: PEP3.2. https://doi.org/10.1530/endoabs.73.PEP3.2 appeared first on Chiasma.
Chiasma Frequently Asked Questions
When was Chiasma founded?
Chiasma was founded in 2001.
Who are Chiasma key executives?
Chiasma's key executives are Roni Mamluk, Dana Gelbaum and Shoshie Katz.
How many employees does Chiasma have?
Chiasma has 48 employees.
What is Chiasma revenue?
Latest Chiasma annual revenue is $1.1 m.
What is Chiasma revenue per employee?
Latest Chiasma revenue per employee is $23 k.
Who are Chiasma competitors?
Competitors of Chiasma include Servier, Laboratorios Bago and USV.
Where is Chiasma headquarters?
Chiasma headquarters is located at 140 Kendrick St Building C, Needham.
Where are Chiasma offices?
Chiasma has offices in Needham, Waltham and Ness Ziona.
How many offices does Chiasma have?
Chiasma has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies